Endo International has completed its acquisition of BioSpecifics Technologies Corp.
Under the terms of a previous strategic relationship, BioSpecifics received royalties from Endo related to Endo's collagenase-based therapies, including XIAFLEX, marketed by Endo Pharmaceuticals, for the treatment of Dupuytren's contracture and Peyronie's disease, and QWO, the first FDA-approved injectable treatment for cellulite, which is expected to be launched by Endo Aesthetics in 2021.
Endo acquired BioSpecifics for $88.50 per share in an all-cash transaction, for an estimated value of $540 million (net of approximately $120 million in cash acquired).
As a result of the acquisition, BioSpecifics ceased to be a publicly traded company and became a wholly-owned subsidiary of Endo.
